As of Q4'25, Johnson & Johnson (JNJ) reported an operating income of USD 5.39B, with a year-over-year growth rate of 50.5%. This marks a significant improvement compared to the previous quarter and highlights a strong finish to the year. Between Q1'23 and Q4'25, JNJ's operating income exhibited notable volatility, with sharp declines in Q4'23 (USD 2.52B, -52.7% YoY) and Q4'24, followed by robust recoveries in subsequent quarters. The overall trend shows periods of both contraction and growth, but the most recent quarters (Q3'25 and Q4'25) demonstrate a strong upward momentum, indicating a potential turnaround and renewed operational strength heading into 2026.